Mifamurtide for the treatment of nonmetastatic osteosarcoma.

The standard treatment for osteosarcoma requires both macroscopic surgical wide resection and postoperative multi-drug chemotherapy in neoadjuvant and adjuvant settings. However, the 5-year event-free survival has remained at a plateau of 60-70% of patients with nonmetastatic osteosarcoma for more than 30 years.
Mifamurtide (liposomal muramyl tripeptide phosphatidylethanolamine; L-MTP-PE) is a new agent. L-MTP-PE is a nonspecific immunomodulator, which is a synthetic analog of a component of bacterial cell walls. L-MTP-PE activates macrophages and monocytes as a potent activator of immune response in addition to standard chemotherapy. It also improves the overall survival from 70 to 78% and results in a one-third reduction in the risk of death from osteosarcoma. This review summarizes the most recent findings about L-MTP-PE and its therapeutic application for nonmetastatic osteosarcoma.
Recently, L-MTP-PE has been approved in Europe for the treatment of nonmetastatic osteosarcoma with chemotherapy. L-MTP-PE in combination with traditional treatment is expected to go mainstream and to be beneficial for patients with osteosarcoma. Information about potential benefit regarding mifamurtide use in the neoadjuvant setting (i.e., before surgery) and/or usefulness of L-MTP-PE in metastatic in relapsed and metastatic osteosarcoma requires analysis of expanded access and/or future clinical trials of L-MTP-PE in high-burden and low-burden situations.
AuthorsKosei Ando, Kanji Mori, Nedège Corradini, Françoise Redini, Dominique Heymann
JournalExpert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 12 Issue 2 Pg. 285-92 (Feb 2011) ISSN: 1744-7666 [Electronic] England
PMID21226638 (Publication Type: Journal Article, Review)
Chemical References
  • Adjuvants, Immunologic
  • Antineoplastic Agents
  • Phosphatidylethanolamines
  • Acetylmuramyl-Alanyl-Isoglutamine
  • mifamurtide
  • Acetylmuramyl-Alanyl-Isoglutamine (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
  • Adjuvants, Immunologic (administration & dosage, adverse effects, therapeutic use)
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Bone Neoplasms (drug therapy, surgery)
  • Disease Progression
  • Humans
  • Neoadjuvant Therapy
  • Osteosarcoma (drug therapy, surgery)
  • Phosphatidylethanolamines (administration & dosage, adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: